Detalles de la búsqueda
1.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621400
2.
A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
Cancer
; 129(7): 1041-1050, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36718624
3.
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Br J Cancer
; 128(8): 1418-1428, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36797356
4.
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Br J Cancer
; 126(4): 576-585, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34795408
5.
Yield of baseline imaging for distant metastases in high-risk primary melanoma.
J Surg Oncol
; 125(8): 1312-1317, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35262187
6.
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
Cancer
; 126(22): 4926-4935, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32809217
7.
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Br J Cancer
; 126(2): 310, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931042
8.
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Br J Cancer
; 117(7): 938-946, 2017 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28950288
9.
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.
J Clin Oncol
; : JCO2302044, 2024 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38900984
10.
A capability framework to inform the fundamental requirements for clinical trial unit development, growth and long term success in outer metropolitan and rural areas.
Contemp Clin Trials Commun
; 32: 101072, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36712185
11.
Immune-related adverse events secondary to immunotherapy in oncology: A guide for general practice.
Aust J Gen Pract
; 52(6): 378-385, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37291817
12.
The role of surveillance imaging for resected high-risk melanoma.
Asia Pac J Clin Oncol
; 19(4): 566-573, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36540019
13.
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
J Immunother Cancer
; 11(2)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36808075
14.
Cardiovascular disease and malignant melanoma.
Melanoma Res
; 32(3): 135-141, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35377865
15.
Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study.
Cardiooncology
; 8(1): 23, 2022 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36461057
16.
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.
Cancers (Basel)
; 14(17)2022 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36077617
17.
Immunotherapy for bladder cancer: rediscovering an old friend.
BJU Int
; 117(5): 721-4, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26389688
18.
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
Clin Lung Cancer
; 22(3): e425-e430, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32778511
19.
Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease.
JCO Precis Oncol
; 5: 561-568, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34994604
20.
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Clin Genitourin Cancer
; 19(5): 434-446, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34006498